ArticleTobacco prevention & cessation2026
Nicotine pouches: A wolf in sheep's clothing.
Article in Tobacco prevention & cessation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Nicotine pouches are a fast-growing class of tobacco-free nicotine products, marketed for oral absorption and often promoted as cleaner alternatives to traditional tobacco. Regulatory efforts to ban flavors such as menthol have been inconsistent, with the US withdrawal of a proposed menthol ban in 2025 intensifying policy instability and raising concerns over youth use. The aim of this monitoring letter is to examine the development of nicotine pouch markets, regulatory responses, and the need for independent research to guide future policy. Sales of nicotine pouches increased dramatically from their US introduction in 2016, with youth uptake rising alongside aggressive marketing and flavored product availability. ZYN commands nearly 68.7% of the youth market, supported by social media campaigns and influencer endorsement. Despite the FDA's 2025 authorization of select ZYN products, most brands remain unregulated. Research primarily sponsored by industry suggests harm reduction, yet independent studies have found carcinogens and toxic metals in some products, and evidence gaps persist regarding health risks and long-term outcomes. International regulation varies, with France instituting a nationwide ban in 2025, contrasting sharply with the US approach. Nicotine pouches continue to expand in both market reach and youth appeal, driven by flavor options and harm-reduction narratives. Regulatory and scientific oversight remain fragmented, echoing previous challenges faced with e-cigarettes. Coordinated policy action and independent research are urgently needed to prevent a repeat of prior youth and public health concerns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.